Health Canada has issued a Notice of Compliance with conditions (NOC/c) for TECVAYLI™ (teclistamab injection)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a...
Read moreResearch & Access Updates
July 2023 Myeloma Research Update
Myeloma Canada, along with thousands from the global hematology community, had the privilege of following...
Read moreSARCLISA (ISATUXIMAB) NOW REIMBURSED IN BC AND ONTARIO
Myeloma Canada is pleased to share that funding for Sarclisa (isatuximab) is officially available in two...
Read moreRapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US
Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announc...
Read moreA phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
In this phase 1/2 study, carfilzomib was added to high-dose melphalan conditioning prior to autologous st...
Read moreNew study gives clues on why exercise helps with inflammation
Researchers have long known that moderate exercise has a beneficial impact on the body’s response to infl...
Read more